A retrospective chart review of pediatric patients with MS at a tertiary treatment center showed how the center’s first ...

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

Recent research has shed new light on multiple sclerosis (MS) in children, who make up about 3% to 5% of the MS population. At one time, children were thought to not experience disability due to their ...

New data from ACTRIMS 2026 suggests biological age acceleration in pediatric MS is not reflected in current clinical or cognitive assessments.

Early treatment of pediatric-onset relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with substantially slower disability progression than treatment with ...

Compared with adult-onset multiple sclerosis (MS), pediatric-onset MS has few treatments directed at the condition, specifically those that promote remyelination, enhance neuroprotection, and ...

Brenda Banwell, MD, Chief, Division of Neurology, Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, said that there are 3 areas of treatment associated with ...

Rates of autoimmune diseases, including thyroid disorders and multiple sclerosis (MS), are higher among families of patients with pediatric MS compared with unaffected families, new research suggests.

Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue ...

Magnetic resonance images (MRI) of patients diagnosed with multiple sclerosis in childhood show that pediatric onset multiple sclerosis is more aggressive and causes more brain lesions than MS ...

While diagnostic criteria for typical multiple sclerosis (MS) perform well in people ages 18 to 50, differential diagnoses in pediatric-onset MS and late-onset MS require specific considerations.